Recent advances in FLT3 and IDH targeted inhibition have improved response rates and overall survival in patients with mutations affecting these respective proteins. Despite this success, resistance mechanisms have arisen including mutations that disrupt inhibitor-target interaction, mutations impacting alternate pathways, and changes in the microenvironment. Here we review the role of these proteins in leukemogenesis, their respective inhibitors, mechanisms of resistance, and briefly ongoing studies aimed at overcoming resistance.

中文翻译：

---

靶向治疗耐药：深入研究 FLT3 和 IDH

FLT3 和 IDH 靶向抑制的最新进展提高了具有影响这些各自蛋白质的突变的患者的反应率和总体存活率。尽管取得了这一成功，但出现了耐药机制，包括破坏抑制剂-靶点相互作用的突变、影响替代途径的突变以及微环境的变化。在这里，我们回顾了这些蛋白质在白血病生成中的作用、它们各自的抑制剂、耐药机制，以及旨在克服耐药性的简要正在进行的研究。